B
Bioyond
Life-science lab automation robots and unattended intelligent lab platforms
About Bioyond
Shanghai Benyao Technology Co., Ltd., operating as Bioyond, is a life sciences company established in March 2021 with headquarters in Shanghai's Zhangjiang Science City. The firm was founded by Tang Yang, who serves as CEO. His background includes extensive experience in the robotics industry, having held leadership roles at ABB Robotics, including President of the China R&D Center and President of the Consumer and Service Robotics Business Unit in China. This experience in robotics and automation is central to Bioyond's operational focus.
The company engineers intelligent automation solutions for the life sciences sector by integrating robotics, artificial intelligence, and high-precision visual recognition technologies. Its business-to-business model serves a client base that includes pharmaceutical companies, clinical diagnostics labs, and scientific research institutions. Bioyond has developed a portfolio of modular automation products and comprehensive solutions designed to address repetitive and labor-intensive tasks in laboratory settings, such as liquid handling and sample preparation. The core of its technology rests on three platforms: robotics, automation, and a data and cloud system. This infrastructure allows for the creation of flexible and rapidly deployable automation systems built from a suite of self-developed robots, instrument modules, and intelligent software. An advanced AI and computing engine enables the processing of large datasets to support scientific analysis and decision-making for R&D and production personnel.
Since its inception, Bioyond has secured significant financial backing. Sequoia China Seed Fund was involved from the incubation stage and provided angel financing in early 2021. The company has since completed multiple funding rounds, including a Pre-A round in the same year led by Qiming Venture Capital, and subsequent Series A and A+ rounds co-led by Boyuan Capital and Lilly Asia Fund (LAV), with participation from CICC Qide Fund. By early 2023, the company had raised approximately 300 million RMB. A Series A3 financing round was announced in October 2024, led by Panlin Capital, with continued investment from existing backers like Qiming Venture Capital and Boyuan Capital. These funds are allocated towards product and technology development, platform construction, and market expansion to enhance automation solutions for its target markets.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Oct 2024 | $28M | $110M | Pan-Lin Asset Management · Qiming Venture Partners · Boyuan Capital | ↗ |
| SERIES AOther financing | Apr 2023 | $28M | $110M | Qiming Venture Partners · Shanghai CICC Capital · Lilly Asia Ventures · HongShan | ↗ |
Growth signals
Latest recorded traffic for Bioyond is 1.5K monthly website visits, up 59.6% over the last three months. Bioyond's team grew 35.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Bioyond in the Pudong ecosystem
The Bioyond office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
HongShan
Qiming Venture Partners- ZIZhangjiang Science and Technology Investment
Series A6 investors entered at this stage
WuXi AppTec
Shanghai CICC Capital
Lilly Asia Ventures
BioTrack Capital
Pan-Lin Asset Management
Boyuan Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bioyond on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bioyond’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









